Semaxanib

Generic Name: Semaxanib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₄N_₂O

CAS Number: 194413-58-6

Unique Ingredient Identifier: 71IA9S35AJ

Indication: Investigated for use/treatment in colorectal cancer and lung cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

Phase 1

Completed

Conditions: Chronic Myelomonocytic Leukemia
Previously Treated Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts
Refractory Anemia With Excess Blasts in Transformation

Interventions: Drug: liposomal daunorubicin citrate
Drug: semaxanib
Other: laboratory biomarker analysis

First Posted Date: 2004-05-26

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00005942

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: semaxanib

First Posted Date: 2004-05-26

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00006001

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

and more 7 locations

SU5416 in Treating Patients With Malignant Mesothelioma

Phase 2

Completed

Conditions: Malignant Mesothelioma

Interventions: Drug: semaxanib

First Posted Date: 2004-02-26

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00006014

Locations: 🇺🇸
Division of Hematology/Oncology, Park Ridge, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
Michiana Hematology/Oncology P.C., South Bend, Indiana, United States

and more 7 locations

SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor
Sarcoma

Interventions: Drug: semaxanib

First Posted Date: 2004-02-12

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00005862

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment

Phase 2

Terminated

Conditions: Recurrent Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Drug: semaxanib

First Posted Date: 2004-01-01

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00009919

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Drug: semaxanib
Drug: thalidomide

First Posted Date: 2003-06-12

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00017316

Locations: 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage III Colon Cancer
Stage III Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions: Drug: irinotecan hydrochloride
Drug: semaxanib
Other: laboratory biomarker analysis

First Posted Date: 2003-05-05

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 68

Registration Number: NCT00005818

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated

Phase 2

Terminated

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: semaxanib
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00006003

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy